COLL Collegium Pharmaceutical Inc.

Collegium to Participate in Upcoming Investor Conference

Collegium to Participate in Upcoming Investor Conference

STOUGHTON, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conference in April:

  • The 19th Annual Needham Healthcare Conference on Tuesday, April 14th. Management will participate in a virtual fireside chat at 1:30 p.m. ET and will also host investor meetings. The presentation will be webcast live and may be accessed from the Investor section of the Company’s website: . A replay of the webcast will be available on the Company’s website.

About Collegium Pharmaceutical, Inc.

Collegium is a specialty pharmaceutical company committed to being the leader in responsible pain management. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the company’s website at .

Contact:

Alex Dasalla

EN
07/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc: 1 director

A director at Collegium Pharmaceutical Inc sold 13,976 shares at 34.924USD and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...

 PRESS RELEASE

Collegium to Present New Real-World Data at PainConnect 2026

Collegium to Present New Real-World Data at PainConnect 2026 STOUGHTON, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: COLL) today announced it will present two posters featuring real-world data from its portfolio of differentiated pain medications at PainConnect 2026, the American Academy of Pain Medicine (AAPM)’s Annual Meeting, taking place in Salt Lake City, Utah from March 5-8, 2026. The presentations highlight real-world clinical insights from Collegium’s pain portfolio and reflect the Company’s continued focus on generating evidence that helps inform everyday practice. “U...

 PRESS RELEASE

Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Em...

Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community – Paris Hilton shares her personal ADHD journey and encourages others to see ADHD in a new light – –Together, Paris and Collegium are reframing common stereotypes and highlighting experiences that are often part of living with ADHD, including the importance of talking to a doctor and finding an individualized treatment plan –          Credit: Ashley Osborn STOUGHTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasd...

 PRESS RELEASE

Collegium to Participate in Upcoming Investor Conferences

Collegium to Participate in Upcoming Investor Conferences STOUGHTON, Mass., March 02, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: Leerink Partners Global Healthcare ConferenceMonday, March 9, 2026Miami, FL Jefferies Biotech on the Beach SummitTuesday, March 10, 2026Miami, FL The Citizens Life Sciences ConferenceTuesday, March 10, 2026Miami, FL Barclays 28th Annual Global Healthcare ConferenceFireside Chat Date and Time: Wednesday, March 11, 2026 at 9:00 a.m. ETMiami, FL A live webcast of the fire...

 PRESS RELEASE

Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results

Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results – Generated Quarterly Net Revenues of $205.4 Million, Up 13% Year-over-Year, and Record Full-Year Net Revenues of $780.6 Million, Up 24% Year-over-Year – – Generated Record Quarterly and Full-Year Jornay PM® Net Revenue of $45.9 Million and $148.9 Million, Up 57% and 48%, Respectively, Year-over-Year – – Generated Quarterly Pain Portfolio Net Revenues of $159.6 Million, Up 5% Year-over-Year, and Record Full-Year Pain Portfolio Net Revenues $631.7 Million, Up 6% Year-over-Year – – Ended 2025 with Cash, Cash Equivalents...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch